To assess the efficacy and safety of apalutamide plus goserelin for androgen receptor (AR)-positive unresectable or recurrent/metastatic salivary gland carcinoma.

AI에게 질문

Bookmark

AI에게 질문

Bookmark

Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU | Synapse

Cite This Study

Honma et al. (Fri,) studied this question.

synapsesocial.com/papers/68e62c14b6db6435875be062 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-24-0455

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma2022 · 43 citations
2

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma2022 · 43 citations
2

Combined androgen blockade in patients with advanced androgen receptor-positive salivary gland carcinoma: Exploratory biomarker analyses2019 · 3 citations

3Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update2018 · 2,461 citations

4Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications2014 · 82 citations

5Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade2021 · 19 citations